Drug intelligence / Profile preview

arginine-alpha-ketoglutarate

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Arginine-alpha-ketoglutarate (AAKG) is a salt formed from the amino acid L-arginine and alpha-ketoglutarate, a key intermediate in the Krebs (citric acid) cycle. AAKG is primarily marketed and used as a dietary supplement, especially among athletes and bodybuilders, for its purported ability to enhance muscle performance, improve exercise recovery, and increase nitric oxide production, leading to vasodilation and enhanced blood flow. The combination of arginine and alpha-ketoglutarate is alleged to improve the stability and availability of arginine, potentially augmenting its performance-enhancing effects compared to L-arginine alone. Mechanistically, arginine is a precursor to nitric oxide, which acts as a vasodilator, while alpha-ketoglutarate participates in energy metabolism and may support protein synthesis and muscle recovery. Despite claims, clinical evidence supporting AAKG's effectiveness for athletic performance enhancement and other health conditions is limited and inconsistent. AAKG is not approved as a pharmaceutical drug and is used as an oral dietary supplement in sports and wellness contexts[7][8][9].

Other names
AAKG
02

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on arginine-alpha-ketoglutarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on arginine-alpha-ketoglutarate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call